Accelerate Deals: Exelixis R&D Trigger
Dana Aftab ramps up R&D at Exelixis. Pitch process optimization to slash drug dev timelines. Add this sales trigger to your pipeline now.
Published on
Do not index
Do not index
🚀 Battle Card: Exelixis, Inc.
Quick trigger: Appointment of Dana T. Aftab, Ph.D. (Aug 29, 2025)
Use this Exelixis sales trigger to focus on R&D excellence.
👤 Decision Maker in the News
- Dana T. Aftab, Ph.D., Executive Vice President, Research and Development · 🔗 LinkedIn
💡 Why It Matters
- This Exelixis sales trigger shows a renewed focus on accelerating drug development pipelines to stay competitive. → Source
🎯 Core Pain Point
- Maintaining seamless handoff between discovery and clinical development
- Scaling translational research to support pivotal trials
💰 What to Pitch
- Primary: R&D Process Optimization Platform → shortens drug development timelines
- Expansion: Clinical Trial Data Management Solution → enhances regulatory readiness
🗺️ Quick Context
- HQ: Alameda, CA
- Employees: ≈ 800
- Rev: ≈ $750 M
- Website: exelixis.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Exelixis’ business.
- Veeva Systems — CTMS & Regulatory
- Unique edge: Industry-standard eTMF and submission tools
- Evaluated by EVP R&D for compliance integration
- Medidata Solutions — Clinical Data & Analytics
- Unique edge: Advanced AI-driven trial insights
- Evaluated by Translational Research leads for data visualization
- Oracle Health Sciences — Integrated R&D Cloud
- Unique edge: End-to-end platform from discovery to safety
- Evaluated by CSO for enterprise scalability
- Parexel — CRO & Consulting
- Unique edge: Deep oncology trial expertise
- Evaluated by VP Clinical Ops for protocol design
✅ Do-Now Checklist
Connect with Dana T. Aftab on LinkedIn
Reference the Exelixis sales trigger in your outreach to highlight timeliness
Pitch the R&D Process Optimization Platform as a quick win
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get more Exelixis sales trigger intel daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑<1-line value>❑
PROOF_METRIC = ❑<metric>❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Dana
COMPANY = Exelixis, Inc.
DEPT = Research and Development
SIZE = ≈ 200
BOTTLENECK = handoff between discovery and clinical development
EVENT = Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
DETAIL = appointment as Executive VP, Research and Development
PAIN = scaling translational research to support pivotal trials
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250829389096&div=41152219
SIM_CO = Genentech
WIN_METRIC = 20% reduction in development cycle time
NEXT_SIZE = ≈ 400
EMP_EST = ≈ 800
REV_EST = ≈ $750M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ 200-person Research and Development
Dana—noticed your Research and Development team is ≈ 200.
That’s when handoff between discovery and clinical development slows growth.
We helped Genentech fix this with ≈ TBD.
Result: 20% reduction in development cycle time.
Quick call?
PS—next bottleneck hits ≈ 400.
DM ≤45 words, TONE:
Saw your post about appointment as Executive VP, Research and Development — scaling translational research to support pivotal trials.
≈ TBD. ≈ TBD.
Quick chat?